World Health Organization pauses hydroxychloroquine trial over safety concerns

World Health Organization pauses hydroxychloroquine trial over safety concerns

Testing of the malaria drug hydroxychloroquine as a possible treatment for coronavirus has been halted because of safety fears, the World Health Organization (WHO) says.

But despite the lack of scientific evidence presenting hydroxychloroquine as a viable coronavirus treatment option, Trump told reporters earlier this month that he has been taking the drug to avoid contracting the disease. The U.S. President has said he was taking the drug to help prevent infection.

"The Executive Group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity Trial while the safety data is reviewed by the Data Safety Monitoring Board", WHO Director-General Tedros Adhanom Ghebreyesus told reporters at a news briefing.

Therefore, researchers said they're suspending use of hydroxychloroquine in the WHO's Solidarity Trial, which is to evaluate the safety and efficacy of four drugs and drug combinations against the virus.

The researchers warned that hydroxychloroquine should not be used outside of clinical trials.

The trial will continue for the other three drugs, and the World Health Organization will likely decide within the next two weeks whether to resume using hydroxychloroquine, chief scientist Soumya Swaminathan told NPR.

'WHO will provide further updates as we know more.

But weeks later, in a statement published online, the International Society of Antimicrobial Chemotherapy (ISAC) addressed several new concerns with the research. To the best of my knowledge, here I am'.

In the United Kingdom, the Principle trials have been looking at hydroxychloroquine among patients between the ages of 50 and 64 who have shown symptoms of COVID-19 and chronic health conditions like cancer, asthma, or heart disease.

"A lot of good things have come out".

The White House declined to comment.

As previously announced, in a study of 1,063 patients sick enough to be hospitalised, the drug shortened the time to recovery by 31 per cent - 11 days on average versus 15 days for those just given usual care.

The risk of developing a serious heart rhythm problem is more than five times greater. Hydroxychloroquine and chloroquine are approved for treating lupus and rheumatoid arthritis and for preventing and treating malaria, but no large rigorous tests have found them safe or effective for preventing or treating COVID-19.

Related Articles